Skip to main content
. 2023 Feb 16;36(2):177–191. doi: 10.3233/CBM-220030

Table 2, continued

PD-L1 in tumor cells PD-L1 in immune cells
Tumor entity On TMA (n) Analyzable (n) Negative (%) Positive (%) Negative (%) Few (%) Many (%)
 Sarcoma, not otherwise specified (NOS) 74 70 62.9 37.1 98.6 1.4 0.0
 Paraganglioma 41 37 94.6 5.4 83.8 8.1 8.1
 Ewing sarcoma 23 20 95.0 5.0 95.0 5.0 0.0
 Rhabdomyosarcoma 6 6 100.0 0.0 100.0 0.0 0.0
 Schwannoma 121 100 98.0 2.0 99.0 1.0 0.0
 Synovial sarcoma 12 11 100.0 0.0 100.0 0.0 0.0
 Osteosarcoma 43 32 100.0 0.0 96.9 3.1 0.0
 Chondrosarcoma 38 19 68.4 31.6 100.0 0.0 0.0